Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa M. Marina, Sigbjørn Smeland, Stefan S. Bielack, Mark Bernstein, Gordana Jovic, Mark D. Krailo, Jane M. Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken L B Brown, Trude Butterfass-Bahloul, Gabriele Calaminus, Heike E. Daldrup-Link, Mikael Eriksson, Mark C. Gebhardt, Hans Gelderblom, Joachim Gerss, Robert GoldsbyAllen Goorin, Richard Gorlick, Holcombe E. Grier, Juliet P. Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S. Hawkins, Knut Helmke, Pancras C W Hogendoorn, Michael S. Isakoff, Katherine A. Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Paul A. Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Papai, R. Lor Randall, Peter Reichardt, Marleen Renard, Akmal Ahmed Safwat, Cindy L. Schwartz, Michael C G Stevens, Sandra J. Strauss, Lisa Teot, Mathias Werner, Matthew R. Sydes, Jeremy S. Whelan
Dive into the research topics of 'Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial'. Together they form a unique fingerprint.